Introduction Traditional beta-blockers have sometimes been associated with erectile
dysfunction (ED). Nebivolol is a cardioselective β1-adrenoceptor antagonist that promotes …

Background: Erectile dysfunction is associated with high blood pressure and
antihypertensive treatment, especially diuretics and traditional β-blockers. Nevertheless …

Introduction The efficacy of oral pharmacotherapy for erectile dysfunction (ED)(ie, type 5
phosphodiesterase [PDE5] inhibitors) is significantly reduced in diabetic patients. Nebivolol …

Introduction Men frequently develop diabetic erectile dysfunction (DMED), as a result of
endothelial dysfunction. DMED patients often have reduced efficacy with phosphodiesterase …

Standard treatments for erectile dysfunction (ED)(ie, PDE5 inhibitors) are less effective in
diabetic patients for unknown reasons. Endothelium-dependent relaxation (EDR) of human …

Erectile function is critically dependent upon the activation of the endothelial nitric oxide
synthase (eNOS) in the smooth muscle cells of penile corpus cavernosum tissue. Nebivolol …

Introduction Diabetic men with erectile dysfunction (ED) are less responsive to therapy with
type 5 phosphodiesterase (PDE5) inhibitors. Although an impairment of the nitric oxide …

Introduction Diabetes mellitus (DM) represents a major risk factor for erectile dysfunction
(ED). Although the etiology of diabetes-induced ED is multifactorial and still unknown …

ABSTRACT Aims and Methods Phosphodiesterase 5 (PDE5) inhibitors are less effective in
the treatment of erectile dysfunction (ED) in diabetic men than in nondiabetic patients. We …

Introduction The combination of the independent risk factors for erectile dysfunction, obesity,
hypertension, and diabetes are manifested collectively in a condition known as metabolic …